Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

NCT01018953 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01018953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01018953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2010
Completion date
January 31, 2011
Enrollment
8 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid syndrome